Nucleome Therapeutics

Nucleome Therapeutics is an Oxford-based biotechnology company focused on decoding the human 'dark genome' - the more than 90% of human genetic material that remains poorly understood - to discover and develop precision medicines for immune-mediated inflammatory diseases.

The company's core technology is its proprietary MCC (Multi-contact Chromatin) platform, which combines pioneering 3D genome sequencing with machine learning to directly link genes to disease and reveal hidden molecular drivers. This approach integrates expertise across genomics, 3D genome sequencing, machine learning, and precision medicine.

Nucleome's pipeline includes NTP-464, a first-in-class precision medicine candidate. The company operates from Oxford, positioning itself within a leading life sciences cluster.